QuidelOrtho Co. (NASDAQ:QDEL) Stock Position Lifted by Amalgamated Bank

Amalgamated Bank grew its position in QuidelOrtho Co. (NASDAQ:QDEL) by 11.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,911 shares of the company’s stock after acquiring an additional 2,014 shares during the quarter. Amalgamated Bank’s holdings in QuidelOrtho were worth $887,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP bought a new stake in QuidelOrtho during the third quarter valued at $25,000. Blue Trust Inc. boosted its holdings in shares of QuidelOrtho by 188.0% in the 4th quarter. Blue Trust Inc. now owns 1,293 shares of the company’s stock valued at $58,000 after buying an additional 844 shares during the period. Spire Wealth Management bought a new stake in shares of QuidelOrtho during the 4th quarter valued at about $74,000. KBC Group NV raised its stake in QuidelOrtho by 122.9% during the fourth quarter. KBC Group NV now owns 3,437 shares of the company’s stock worth $153,000 after acquiring an additional 1,895 shares during the period. Finally, International Assets Investment Management LLC lifted its holdings in QuidelOrtho by 4,460.0% in the third quarter. International Assets Investment Management LLC now owns 4,560 shares of the company’s stock worth $208,000 after acquiring an additional 4,460 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Brian J. Blaser bought 6,033 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was purchased at an average cost of $41.42 per share, for a total transaction of $249,886.86. Following the completion of the transaction, the chief executive officer now directly owns 6,033 shares of the company’s stock, valued at approximately $249,886.86. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.00% of the company’s stock.

QuidelOrtho Trading Down 2.4 %

NASDAQ:QDEL opened at $39.05 on Tuesday. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of -1.29 and a beta of 0.08. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22. QuidelOrtho Co. has a 1 year low of $29.74 and a 1 year high of $49.45. The business has a fifty day moving average of $43.07 and a 200-day moving average of $42.31.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. Equities analysts predict that QuidelOrtho Co. will post 2.3 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on QDEL. Royal Bank of Canada lowered their target price on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a report on Thursday, February 13th. Citigroup upgraded QuidelOrtho from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $44.00 to $50.00 in a research note on Wednesday, December 11th. Jefferies Financial Group initiated coverage on QuidelOrtho in a research note on Tuesday, December 10th. They issued a “hold” rating and a $43.00 target price on the stock. StockNews.com lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Finally, William Blair reiterated a “market perform” rating on shares of QuidelOrtho in a research report on Wednesday, November 20th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $51.20.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.